Human services: medical services; coverage for treatment of menopause and perimenopause symptoms and waiver of prior authorization for prescription drugs or treatments for menopause and perimenopause symptoms; require. Amends sec. 109h of 1939 PA 280 (MCL 400.109h) & adds sec. 109t.
Impact
The passage of HB4815 would make a significant impact on state laws concerning healthcare coverage, particularly regarding the treatment for menopause and perimenopause. By eliminating prior authorization for specific categories of prescription medications, including various central nervous system drugs and therapies for cancer and substance use disorders, the bill would streamline access to necessary medical care. This change is designed to enhance patient care and potentially reduce delays in treatment, ultimately providing individuals with timely access to medicines they need.
Summary
House Bill 4815 aims to amend the 1939 PA 280, commonly referred to as 'The Social Welfare Act,' specifically targeting the processes and criteria surrounding prescription drug authorizations within the medical assistance program in Michigan. This legislation introduces provisions that would waive prior authorization requirements for certain prescription drugs used to treat various medical conditions, including those relating to menopause and perimenopause. By ensuring that treatments for these conditions, such as hormone replacement therapy, are readily accessible without prior authorization, the bill seeks to improve the quality of care for individuals experiencing menopause symptoms.
Contention
While the bill presents numerous beneficial aspects, it is not without contention. Some stakeholders may express concerns regarding the potential implications of loosening prior authorization requirements, fearing it could lead to overprescription and potential misuse of certain medications. Conversely, advocates argue that the current authorization processes can be barriers that prevent timely access to critical medications. There may be pushback from entities focused on healthcare cost control and regulation, highlighting the need to balance accessibility with responsible prescribing practices.
Human services: medical services; coverage for treatment of menopause and perimenopause symptoms and waiver of prior authorization for prescription drugs or treatments for menopause and perimenopause symptoms; require. Amends sec. 109h of 1939 PA 280 (MCL 400.109h) & adds sec. 109t.
Insurance: health insurers; coverage for treatment of menopause and perimenopause symptoms and waiver of prior authorization for prescription drugs or treatments for menopause and perimenopause symptoms; require. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406zz.
Insurance: health insurers; coverage for treatment of menopause and perimenopause symptoms and waiver of prior authorization for prescription drugs or treatments for menopause and perimenopause symptoms; require. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406zz.
Human services: medical services; exemption of certain prescription drugs for the treatment or management of pain from the medical assistance prior authorization process; provide for. Amends sec. 109h of 1939 PA 280 (MCL 400.109h) & adds sec. 109v.
Human services: medical services; exemption of certain prescription drugs from the medical assistance prior authorization process; provide for. Amends sec. 109h of 1939 PA 280 (MCL 400.109h).
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.